Perioperative Nivolumab Does Not Sacrifice QoL in NSCLC
Perioperative nivolumab in eligible patients with resectable non-small cell lung cancer offers improved survival outcomes and preserves quality of life, new data show.
Medscape Medical News
source https://www.medscape.com/viewarticle/perioperative-nivolumab-does-not-sacrifice-qol-nsclc-2025a1000nl9?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/perioperative-nivolumab-does-not-sacrifice-qol-nsclc-2025a1000nl9?src=rss
Comments
Post a Comment